Cell Counting Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Cell Counting Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Cell Counting Market is projected to register a CAGR of 7.2% over the forecast period (2022 - 2027).

COVID-19 had a significant impact on the adoption of cell counting products and consumables. The pandemic witnessed increased adoption of cell counting devices, as osteopenia and lymphopenia are the potential indicators of COVID-19. The study published in BMC Infectious Diseases, titled "Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study" in June 2021, found that in COVID-19 patients, the high WBC count upon admission was significantly linked to death. As a result, in the therapy of COVID-19, a higher WBC count should be given more consideration. Thus, COVID-19 pandemic had a pronounced impact on the growth of the market.

The major factors contributing to the market's growth are the rising incidence of target diseases like HIV, measles, diphtheria, and chronic diseases like cancer and other blood disorders; and the growing use of high-throughput flow cytometry and automated hematology analyzers.

According to the World Health Organization (WHO) November 2021 update, it was estimated that nearly 37.7 million individuals had HIV globally at the end of 2020. The same source also mentioned that in 2020, 680,000 individuals died from HIV-related causes, while 1.5 million contracted the virus. In recent years, portable point-of-care (POC) CD4 T-cell counting devices have been created specifically to increase access to affordable HIV+ patient monitoring in low-income nations. Thus, rising cases of infectious diseases are ultimately expected to increase the demand in the cell counting products and consumables.

Furthermore, technological advancements in cell counting products and consumables have led to increased product launches and, thereby, increased adoption, in turn driving market growth. For instance, in February 2021, the CountWire System was officially launched by Logos Biosystems, a premier provider of innovative life science solutions and Aligned Genetics, Inc. subsidiary.

Therefore, the rising prevalence of chronic diseases, growing technological advancements, and product launches in the cell counting market, among others, are expected to drive the growth of this market. However, the high cost of advanced cell counting systems and product recalls of hematology analyzers are expected to hamper the market's growth.

The instruments segment is expected to hold a significant share over the forecast period. The dominant share of the segment is attributed to the increasing usage of cell counters in various applications, like research, diagnostics, and industrial. Cell counting instruments are increasingly being adopted in various research areas, such as cancer biology, immunology, and neuroscience, which displays exponential growth opportunities for the market segment.

According to the study published in Multidisciplinary Digital Publishing Institute, titled "Potential of an Automated- and Image-Based Cell Counter to Accelerate Microalgal Research and Applications" in November 2020, an automated and image-based cell counter contributes to the creation of routine microalgae management with a reduced work burden when compared to traditional approaches such as hemocytometry and turbidity. The importance and efficiency of cell counter instruments will lead to increased demand for these instruments, which is expected to propel the instrument segment's growth over the coming years.

Furthermore, rising initiatives from the key market players to launch advanced cell counter devices have led to increased adoption of these devices due to their diverse applications and ease of workflow. For instance, in June 2021, one of the first fluorescent cell counters from CytoSMART Technologies was introduced. The CytoSMART Exact FL is a fully automated dual fluorescence cell counter with super robust image recognition by artificial intelligence (AI) algorithms. The rise in product advancements will lead to higher adoption, thereby driving this segment's growth.

Moreover, the rising prevalence of chronic blood-related disorders is also expected to contribute to this segment's growth. For instance, according to GLOBOCAN 2020, there were 274,519 new cases of leUnited Kingdomemia in the world in 2020. Such a high incidence of diseases creates the need for proper diagnosis and treatment, thereby driving the growth of the market segment.

Therefore, the instruments segment is expected to be driven over the forecast period due to the above factors.

North America holds a major share in the market and is expected to do the same in the overall cell counting market throughout the forecast period. The significant market share is mainly due to a larger patient pool, rising use of high-throughput flow cytometry and automated hematology analyzers across healthcare settings, and the presence of key players in the region.

United States holds the largest market share in the North American region due to factors such as the increasing number of chronic diseases and a growing number of research and development activities in the country. According to the American Cancer Society's 2022 statistics, in United States, there will be 290,560 new cases of breast cancer, 268,490 new cases of prostate cancer, and 236,740 new cases of lung and bronchus cancer in 2022. Such a high burden of cancer creates the need for a proper diagnosis and thus drives the growth of the market in the region.

Furthermore, the rise in product launches by companies in United States will further lead to increased adoption of these devices, thereby propelling the growth of this market in North America. For instance, in January 2020, Beckman Coulter, a global pioneer in clinical diagnostics, launched the DxH 560 AL, a tabletop analyzer designed to help small and mid-sized laboratories overcome time and budget restrictions.

Therefore, owing to the above factors, the North American region is expected to show significant growth over the forecast period.

The cell counting market is moderately competitive. A few of the crucial approaches followed by players are product advancement, invention, acquisitions, and mergers. Some of the companies currently dominating the market are Danaher Corporation, Thermo Fisher Scientific, Becton, Dickinson and Company, Merck, Bio-Rad Laboratories, and GE Healthcare, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support